Groups Target EU-Mercosur FTA To Advance Access To Health In Trade Deals 16/05/2018 Monika Ermert AIDS activists, health activists and civil society organizations in Brazil and Argentina are pushing back against the negative effects of the planned free trade agreement between the Mercosur countries and the European Union. The EU-Mercosur negotiations might be the best chance as of now to advance an intellectual property agenda that is more favourable to access to health, says Pedro Villardi, coordinator on IP policy issues at the Associação Brasiliera Interdisciplinar de Aids Observatorio National de Politicas de Aids (ABIA). Continue reading -> EU Commission Outlines Approach On Artificial Intelligence 25/04/2018 William New The European Commission today issued an outline of a European approach on artificial intelligence to "boost investment and set ethical guidelines." The aim is to have a coordinated plan with member states by year's end. Continue reading -> At Geneva Health Forum: Importance Of High Quality Of Health Systems, Beyond Access 11/04/2018 Catherine Saez Achieving a high percentage of universal health coverage often does not translate into a high quality of health systems, according to speakers at the opening of the Geneva Health Forum. While in developed countries people are demanding better quality, the expectations of people living in low and middle-income countries need to be raised, they said. Another panel looked at the use of big data and mathematical modelling as ways to improve health systems, including Facebook monitoring. Continue reading -> Sir John Sulston, Human Genome Project Leader, Remembered For Words On IP And Health R&D 14/03/2018 William New Nobel Prize winner Sir John Sulston passed away on 6 March at the age of 75, and was widely remembered in the press and scientific circles, celebrating his research, his wisdom, and his leadership of the landmark Human Genome Project. Intellectual Property Watch recalls his visionary warning and advice a decade ago about the intellectual property system, investment, and science that is still valuable today. Continue reading -> New IP-Sharing Framework To Accelerate R&D 12/03/2018 Guest contributor Pharmaceutical R&D constantly leads to the generation of new intellectual property (IP), from clinical trial data to libraries of promising compounds. Not all IP assets generated by a company are used in their future R&D. When this happens, companies can choose instead to share them with other third-party researchers, under licensing agreements. The Access to Medicine Foundation has worked with BIO Ventures for Global Health (BVGH) to develop a framework for identifying which IP assets are most difficult for companies to share, yet most likely to speed up R&D of the medicines and vaccines needed by people living in low- and middle-income countries (LMICs), write Clarke B. Cole and Katie Graef. Continue reading -> Wellcome Trust Report Recommends UK-EU Agreement On Research & Innovation 27/02/2018 William New The Wellcome Trust, the London-based biomedical research charity, has issued recommendations for improved scientific collaboration after Brexit, including to establish a formal agreement on research and innovation. This includes continued leadership by the UK on open research, and might include expanding the UK patent box scheme, it says. Continue reading -> Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices 26/02/2018 Catherine Saez Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it. Continue reading -> Innovations For All: Swiss-Led Panel Looks At What Works, What Doesn’t 14/02/2018 William New The current innovation system has yielded many important innovations and extended human life, nobody disputes this. But what about the cases where it hasn’t and a problem persists? A panel of health experts organised recently by the Swiss government and including representatives of the pharmaceutical industry, the World Health Organization, academia, and a research institution held an unusually open and positive discussion that sought to get underneath the issue. Continue reading -> Do We Need A Global Body To Set Priorities For Diseases And Research? 14/02/2018 William New A recent panel of health experts gathered at the hallowed Swiss Intellectual Property Institute in Bern (which counts Albert Einstein among its alumni) tackled some of the toughest questions facing global health policymakers with an eye toward actually solving them and not just restating polarised positions. One of the ideas discussed at the event was how priorities for diseases and research are handled at the global level. Continue reading -> Medicines Innovation And Access: Swiss Stimulate New Thinking 06/02/2018 Catherine Saez BERN, Switzerland -- What if reaching the United Nations Sustainable Development Goals on access to health for all depended on the willingness of all actors to see beyond outdated dichotomies? The concept may seem obvious, but is easier described than done. In an effort to break silos, the Swiss Federal Institute of Intellectual Property (IPI) brought together stakeholders of all sides last week to discuss how to harness political and economic will to achieve innovation leading to new medicines that are available and affordable for all in need. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
EU Commission Outlines Approach On Artificial Intelligence 25/04/2018 William New The European Commission today issued an outline of a European approach on artificial intelligence to "boost investment and set ethical guidelines." The aim is to have a coordinated plan with member states by year's end. Continue reading -> At Geneva Health Forum: Importance Of High Quality Of Health Systems, Beyond Access 11/04/2018 Catherine Saez Achieving a high percentage of universal health coverage often does not translate into a high quality of health systems, according to speakers at the opening of the Geneva Health Forum. While in developed countries people are demanding better quality, the expectations of people living in low and middle-income countries need to be raised, they said. Another panel looked at the use of big data and mathematical modelling as ways to improve health systems, including Facebook monitoring. Continue reading -> Sir John Sulston, Human Genome Project Leader, Remembered For Words On IP And Health R&D 14/03/2018 William New Nobel Prize winner Sir John Sulston passed away on 6 March at the age of 75, and was widely remembered in the press and scientific circles, celebrating his research, his wisdom, and his leadership of the landmark Human Genome Project. Intellectual Property Watch recalls his visionary warning and advice a decade ago about the intellectual property system, investment, and science that is still valuable today. Continue reading -> New IP-Sharing Framework To Accelerate R&D 12/03/2018 Guest contributor Pharmaceutical R&D constantly leads to the generation of new intellectual property (IP), from clinical trial data to libraries of promising compounds. Not all IP assets generated by a company are used in their future R&D. When this happens, companies can choose instead to share them with other third-party researchers, under licensing agreements. The Access to Medicine Foundation has worked with BIO Ventures for Global Health (BVGH) to develop a framework for identifying which IP assets are most difficult for companies to share, yet most likely to speed up R&D of the medicines and vaccines needed by people living in low- and middle-income countries (LMICs), write Clarke B. Cole and Katie Graef. Continue reading -> Wellcome Trust Report Recommends UK-EU Agreement On Research & Innovation 27/02/2018 William New The Wellcome Trust, the London-based biomedical research charity, has issued recommendations for improved scientific collaboration after Brexit, including to establish a formal agreement on research and innovation. This includes continued leadership by the UK on open research, and might include expanding the UK patent box scheme, it says. Continue reading -> Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices 26/02/2018 Catherine Saez Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it. Continue reading -> Innovations For All: Swiss-Led Panel Looks At What Works, What Doesn’t 14/02/2018 William New The current innovation system has yielded many important innovations and extended human life, nobody disputes this. But what about the cases where it hasn’t and a problem persists? A panel of health experts organised recently by the Swiss government and including representatives of the pharmaceutical industry, the World Health Organization, academia, and a research institution held an unusually open and positive discussion that sought to get underneath the issue. Continue reading -> Do We Need A Global Body To Set Priorities For Diseases And Research? 14/02/2018 William New A recent panel of health experts gathered at the hallowed Swiss Intellectual Property Institute in Bern (which counts Albert Einstein among its alumni) tackled some of the toughest questions facing global health policymakers with an eye toward actually solving them and not just restating polarised positions. One of the ideas discussed at the event was how priorities for diseases and research are handled at the global level. Continue reading -> Medicines Innovation And Access: Swiss Stimulate New Thinking 06/02/2018 Catherine Saez BERN, Switzerland -- What if reaching the United Nations Sustainable Development Goals on access to health for all depended on the willingness of all actors to see beyond outdated dichotomies? The concept may seem obvious, but is easier described than done. In an effort to break silos, the Swiss Federal Institute of Intellectual Property (IPI) brought together stakeholders of all sides last week to discuss how to harness political and economic will to achieve innovation leading to new medicines that are available and affordable for all in need. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
At Geneva Health Forum: Importance Of High Quality Of Health Systems, Beyond Access 11/04/2018 Catherine Saez Achieving a high percentage of universal health coverage often does not translate into a high quality of health systems, according to speakers at the opening of the Geneva Health Forum. While in developed countries people are demanding better quality, the expectations of people living in low and middle-income countries need to be raised, they said. Another panel looked at the use of big data and mathematical modelling as ways to improve health systems, including Facebook monitoring. Continue reading -> Sir John Sulston, Human Genome Project Leader, Remembered For Words On IP And Health R&D 14/03/2018 William New Nobel Prize winner Sir John Sulston passed away on 6 March at the age of 75, and was widely remembered in the press and scientific circles, celebrating his research, his wisdom, and his leadership of the landmark Human Genome Project. Intellectual Property Watch recalls his visionary warning and advice a decade ago about the intellectual property system, investment, and science that is still valuable today. Continue reading -> New IP-Sharing Framework To Accelerate R&D 12/03/2018 Guest contributor Pharmaceutical R&D constantly leads to the generation of new intellectual property (IP), from clinical trial data to libraries of promising compounds. Not all IP assets generated by a company are used in their future R&D. When this happens, companies can choose instead to share them with other third-party researchers, under licensing agreements. The Access to Medicine Foundation has worked with BIO Ventures for Global Health (BVGH) to develop a framework for identifying which IP assets are most difficult for companies to share, yet most likely to speed up R&D of the medicines and vaccines needed by people living in low- and middle-income countries (LMICs), write Clarke B. Cole and Katie Graef. Continue reading -> Wellcome Trust Report Recommends UK-EU Agreement On Research & Innovation 27/02/2018 William New The Wellcome Trust, the London-based biomedical research charity, has issued recommendations for improved scientific collaboration after Brexit, including to establish a formal agreement on research and innovation. This includes continued leadership by the UK on open research, and might include expanding the UK patent box scheme, it says. Continue reading -> Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices 26/02/2018 Catherine Saez Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it. Continue reading -> Innovations For All: Swiss-Led Panel Looks At What Works, What Doesn’t 14/02/2018 William New The current innovation system has yielded many important innovations and extended human life, nobody disputes this. But what about the cases where it hasn’t and a problem persists? A panel of health experts organised recently by the Swiss government and including representatives of the pharmaceutical industry, the World Health Organization, academia, and a research institution held an unusually open and positive discussion that sought to get underneath the issue. Continue reading -> Do We Need A Global Body To Set Priorities For Diseases And Research? 14/02/2018 William New A recent panel of health experts gathered at the hallowed Swiss Intellectual Property Institute in Bern (which counts Albert Einstein among its alumni) tackled some of the toughest questions facing global health policymakers with an eye toward actually solving them and not just restating polarised positions. One of the ideas discussed at the event was how priorities for diseases and research are handled at the global level. Continue reading -> Medicines Innovation And Access: Swiss Stimulate New Thinking 06/02/2018 Catherine Saez BERN, Switzerland -- What if reaching the United Nations Sustainable Development Goals on access to health for all depended on the willingness of all actors to see beyond outdated dichotomies? The concept may seem obvious, but is easier described than done. In an effort to break silos, the Swiss Federal Institute of Intellectual Property (IPI) brought together stakeholders of all sides last week to discuss how to harness political and economic will to achieve innovation leading to new medicines that are available and affordable for all in need. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Sir John Sulston, Human Genome Project Leader, Remembered For Words On IP And Health R&D 14/03/2018 William New Nobel Prize winner Sir John Sulston passed away on 6 March at the age of 75, and was widely remembered in the press and scientific circles, celebrating his research, his wisdom, and his leadership of the landmark Human Genome Project. Intellectual Property Watch recalls his visionary warning and advice a decade ago about the intellectual property system, investment, and science that is still valuable today. Continue reading -> New IP-Sharing Framework To Accelerate R&D 12/03/2018 Guest contributor Pharmaceutical R&D constantly leads to the generation of new intellectual property (IP), from clinical trial data to libraries of promising compounds. Not all IP assets generated by a company are used in their future R&D. When this happens, companies can choose instead to share them with other third-party researchers, under licensing agreements. The Access to Medicine Foundation has worked with BIO Ventures for Global Health (BVGH) to develop a framework for identifying which IP assets are most difficult for companies to share, yet most likely to speed up R&D of the medicines and vaccines needed by people living in low- and middle-income countries (LMICs), write Clarke B. Cole and Katie Graef. Continue reading -> Wellcome Trust Report Recommends UK-EU Agreement On Research & Innovation 27/02/2018 William New The Wellcome Trust, the London-based biomedical research charity, has issued recommendations for improved scientific collaboration after Brexit, including to establish a formal agreement on research and innovation. This includes continued leadership by the UK on open research, and might include expanding the UK patent box scheme, it says. Continue reading -> Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices 26/02/2018 Catherine Saez Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it. Continue reading -> Innovations For All: Swiss-Led Panel Looks At What Works, What Doesn’t 14/02/2018 William New The current innovation system has yielded many important innovations and extended human life, nobody disputes this. But what about the cases where it hasn’t and a problem persists? A panel of health experts organised recently by the Swiss government and including representatives of the pharmaceutical industry, the World Health Organization, academia, and a research institution held an unusually open and positive discussion that sought to get underneath the issue. Continue reading -> Do We Need A Global Body To Set Priorities For Diseases And Research? 14/02/2018 William New A recent panel of health experts gathered at the hallowed Swiss Intellectual Property Institute in Bern (which counts Albert Einstein among its alumni) tackled some of the toughest questions facing global health policymakers with an eye toward actually solving them and not just restating polarised positions. One of the ideas discussed at the event was how priorities for diseases and research are handled at the global level. Continue reading -> Medicines Innovation And Access: Swiss Stimulate New Thinking 06/02/2018 Catherine Saez BERN, Switzerland -- What if reaching the United Nations Sustainable Development Goals on access to health for all depended on the willingness of all actors to see beyond outdated dichotomies? The concept may seem obvious, but is easier described than done. In an effort to break silos, the Swiss Federal Institute of Intellectual Property (IPI) brought together stakeholders of all sides last week to discuss how to harness political and economic will to achieve innovation leading to new medicines that are available and affordable for all in need. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New IP-Sharing Framework To Accelerate R&D 12/03/2018 Guest contributor Pharmaceutical R&D constantly leads to the generation of new intellectual property (IP), from clinical trial data to libraries of promising compounds. Not all IP assets generated by a company are used in their future R&D. When this happens, companies can choose instead to share them with other third-party researchers, under licensing agreements. The Access to Medicine Foundation has worked with BIO Ventures for Global Health (BVGH) to develop a framework for identifying which IP assets are most difficult for companies to share, yet most likely to speed up R&D of the medicines and vaccines needed by people living in low- and middle-income countries (LMICs), write Clarke B. Cole and Katie Graef. Continue reading -> Wellcome Trust Report Recommends UK-EU Agreement On Research & Innovation 27/02/2018 William New The Wellcome Trust, the London-based biomedical research charity, has issued recommendations for improved scientific collaboration after Brexit, including to establish a formal agreement on research and innovation. This includes continued leadership by the UK on open research, and might include expanding the UK patent box scheme, it says. Continue reading -> Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices 26/02/2018 Catherine Saez Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it. Continue reading -> Innovations For All: Swiss-Led Panel Looks At What Works, What Doesn’t 14/02/2018 William New The current innovation system has yielded many important innovations and extended human life, nobody disputes this. But what about the cases where it hasn’t and a problem persists? A panel of health experts organised recently by the Swiss government and including representatives of the pharmaceutical industry, the World Health Organization, academia, and a research institution held an unusually open and positive discussion that sought to get underneath the issue. Continue reading -> Do We Need A Global Body To Set Priorities For Diseases And Research? 14/02/2018 William New A recent panel of health experts gathered at the hallowed Swiss Intellectual Property Institute in Bern (which counts Albert Einstein among its alumni) tackled some of the toughest questions facing global health policymakers with an eye toward actually solving them and not just restating polarised positions. One of the ideas discussed at the event was how priorities for diseases and research are handled at the global level. Continue reading -> Medicines Innovation And Access: Swiss Stimulate New Thinking 06/02/2018 Catherine Saez BERN, Switzerland -- What if reaching the United Nations Sustainable Development Goals on access to health for all depended on the willingness of all actors to see beyond outdated dichotomies? The concept may seem obvious, but is easier described than done. In an effort to break silos, the Swiss Federal Institute of Intellectual Property (IPI) brought together stakeholders of all sides last week to discuss how to harness political and economic will to achieve innovation leading to new medicines that are available and affordable for all in need. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Wellcome Trust Report Recommends UK-EU Agreement On Research & Innovation 27/02/2018 William New The Wellcome Trust, the London-based biomedical research charity, has issued recommendations for improved scientific collaboration after Brexit, including to establish a formal agreement on research and innovation. This includes continued leadership by the UK on open research, and might include expanding the UK patent box scheme, it says. Continue reading -> Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices 26/02/2018 Catherine Saez Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it. Continue reading -> Innovations For All: Swiss-Led Panel Looks At What Works, What Doesn’t 14/02/2018 William New The current innovation system has yielded many important innovations and extended human life, nobody disputes this. But what about the cases where it hasn’t and a problem persists? A panel of health experts organised recently by the Swiss government and including representatives of the pharmaceutical industry, the World Health Organization, academia, and a research institution held an unusually open and positive discussion that sought to get underneath the issue. Continue reading -> Do We Need A Global Body To Set Priorities For Diseases And Research? 14/02/2018 William New A recent panel of health experts gathered at the hallowed Swiss Intellectual Property Institute in Bern (which counts Albert Einstein among its alumni) tackled some of the toughest questions facing global health policymakers with an eye toward actually solving them and not just restating polarised positions. One of the ideas discussed at the event was how priorities for diseases and research are handled at the global level. Continue reading -> Medicines Innovation And Access: Swiss Stimulate New Thinking 06/02/2018 Catherine Saez BERN, Switzerland -- What if reaching the United Nations Sustainable Development Goals on access to health for all depended on the willingness of all actors to see beyond outdated dichotomies? The concept may seem obvious, but is easier described than done. In an effort to break silos, the Swiss Federal Institute of Intellectual Property (IPI) brought together stakeholders of all sides last week to discuss how to harness political and economic will to achieve innovation leading to new medicines that are available and affordable for all in need. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices 26/02/2018 Catherine Saez Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it. Continue reading -> Innovations For All: Swiss-Led Panel Looks At What Works, What Doesn’t 14/02/2018 William New The current innovation system has yielded many important innovations and extended human life, nobody disputes this. But what about the cases where it hasn’t and a problem persists? A panel of health experts organised recently by the Swiss government and including representatives of the pharmaceutical industry, the World Health Organization, academia, and a research institution held an unusually open and positive discussion that sought to get underneath the issue. Continue reading -> Do We Need A Global Body To Set Priorities For Diseases And Research? 14/02/2018 William New A recent panel of health experts gathered at the hallowed Swiss Intellectual Property Institute in Bern (which counts Albert Einstein among its alumni) tackled some of the toughest questions facing global health policymakers with an eye toward actually solving them and not just restating polarised positions. One of the ideas discussed at the event was how priorities for diseases and research are handled at the global level. Continue reading -> Medicines Innovation And Access: Swiss Stimulate New Thinking 06/02/2018 Catherine Saez BERN, Switzerland -- What if reaching the United Nations Sustainable Development Goals on access to health for all depended on the willingness of all actors to see beyond outdated dichotomies? The concept may seem obvious, but is easier described than done. In an effort to break silos, the Swiss Federal Institute of Intellectual Property (IPI) brought together stakeholders of all sides last week to discuss how to harness political and economic will to achieve innovation leading to new medicines that are available and affordable for all in need. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Innovations For All: Swiss-Led Panel Looks At What Works, What Doesn’t 14/02/2018 William New The current innovation system has yielded many important innovations and extended human life, nobody disputes this. But what about the cases where it hasn’t and a problem persists? A panel of health experts organised recently by the Swiss government and including representatives of the pharmaceutical industry, the World Health Organization, academia, and a research institution held an unusually open and positive discussion that sought to get underneath the issue. Continue reading -> Do We Need A Global Body To Set Priorities For Diseases And Research? 14/02/2018 William New A recent panel of health experts gathered at the hallowed Swiss Intellectual Property Institute in Bern (which counts Albert Einstein among its alumni) tackled some of the toughest questions facing global health policymakers with an eye toward actually solving them and not just restating polarised positions. One of the ideas discussed at the event was how priorities for diseases and research are handled at the global level. Continue reading -> Medicines Innovation And Access: Swiss Stimulate New Thinking 06/02/2018 Catherine Saez BERN, Switzerland -- What if reaching the United Nations Sustainable Development Goals on access to health for all depended on the willingness of all actors to see beyond outdated dichotomies? The concept may seem obvious, but is easier described than done. In an effort to break silos, the Swiss Federal Institute of Intellectual Property (IPI) brought together stakeholders of all sides last week to discuss how to harness political and economic will to achieve innovation leading to new medicines that are available and affordable for all in need. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Do We Need A Global Body To Set Priorities For Diseases And Research? 14/02/2018 William New A recent panel of health experts gathered at the hallowed Swiss Intellectual Property Institute in Bern (which counts Albert Einstein among its alumni) tackled some of the toughest questions facing global health policymakers with an eye toward actually solving them and not just restating polarised positions. One of the ideas discussed at the event was how priorities for diseases and research are handled at the global level. Continue reading -> Medicines Innovation And Access: Swiss Stimulate New Thinking 06/02/2018 Catherine Saez BERN, Switzerland -- What if reaching the United Nations Sustainable Development Goals on access to health for all depended on the willingness of all actors to see beyond outdated dichotomies? The concept may seem obvious, but is easier described than done. In an effort to break silos, the Swiss Federal Institute of Intellectual Property (IPI) brought together stakeholders of all sides last week to discuss how to harness political and economic will to achieve innovation leading to new medicines that are available and affordable for all in need. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Medicines Innovation And Access: Swiss Stimulate New Thinking 06/02/2018 Catherine Saez BERN, Switzerland -- What if reaching the United Nations Sustainable Development Goals on access to health for all depended on the willingness of all actors to see beyond outdated dichotomies? The concept may seem obvious, but is easier described than done. In an effort to break silos, the Swiss Federal Institute of Intellectual Property (IPI) brought together stakeholders of all sides last week to discuss how to harness political and economic will to achieve innovation leading to new medicines that are available and affordable for all in need. Continue reading -> Posts navigation Older postsNewer posts